Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 38

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors

Kim, Ji‐Yeon, Jung, Jaeyun, Kim, Kyoung‐Mee, Lee, Jeeyun, Im, Young‐Hyuck · 2023 · Cancer Medicine

Abstract

Background: TP53 is the most commonly mutated gene across all cancer types. R175H mutation was considered structural mutation where the mutation causes misfolding of the protein and leads to a significant conformational alterations within p53's DNA binding domain. The aim of this study was to explain the reason why R175H worse the response to immunotherapy by analyzing tumor immune microenvironment through the expression of immune cells and PD‐1. Materials and Methods: Patients diagnosed with metastatic carcinoma, including colorectal cancer (CRC), breast cancer (BRCA), gastric cancer (GC), non‐small cell lung cancer (NSCLC), and 20 other cancer types, treated in a palliative setting at Samsung Medical Center between October 2019 and April 2021, were enrolled. Of these patients, those who underwent TDS analysis (TruSight™ Oncology 500 assay [TSO 500]) were finally analyzed. Results: Of 1770 patients, 1012 (57.2%) harbored genetic alterations in TP53. All mutations were single nucleotide variants (SNVs), and the most frequent SNV was R175H ( n = 84, 7.5%) which was known as one of the most common hotspot TP53 mutation. The overall survival of patients with TP53 R175H mutations was significantly worse following chemotherapy (606 vs. 456 days, p < 0.001) or immunotherapy (822 vs. 350 days, p < 0.001) compared to those with TP53 mutation in other loci. RNA sequencing indicated that the immune response‐related pathways were downregulated in tumors harboring TP53 R175H mutation. Moreover, the expression of CD8(+) T cells PD‐1 were lowered in R175H mutation tumors. In the analysis of TP53 structural domain, compared to those having TP53 mutation in other domain, patients with mutations occurring in the nuclear exporter signal (NES) and E4F1‐binding domains had significantly worse overall survival following chemotherapy (NES: 606 vs. 451 days, p = 0.043; E4F1: 606 vs. 469 days, p = 0.046) and immunotherapy (NES: 822 vs. 403 days, p < 0.001; E4F1: 822 vs. 413 days, p < 0.001). In addition, tumors with TP53 mutation and co‐existing copy number amplification of CCND1, FGF4, and FGF19 in chromosome 11 conferred worse prognosis than those with only TP53 mutation ( p < 0.050). Discussion: Each TP53 mutations indicated differential treatment outcomes following chemotherapy or immunotherapy in patients with metastatic cancer. Functional analysis including RNASeq suggested that TP53 mutation downregulated immune response. Conclusion: Overall, we found each TP53 mutation to indicate different prognoses in patients with metastatic tumors undergoing chemotherapy and ICI treatment. Further validations, including a prospective cohort study or a functional study, would be particularly valuable in advancing the knowledge on this aspect and developing improved prognostic parameters.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cam4.5953

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 31

  1. HassinO NatarajNB Shreberk‐ShakedM et al.Different Hotspot p53 Mutants Exert Distinct Phenotypes and Predict Outcome of Colorectal Cancer Patients.2022;13:1‐15. · DOI
  2. 10.1016/S0304-419X(02)00035-5 · DOI · Paper page
  3. 10.1038/ncb2641 · DOI · Paper page
  4. 10.1038/ng.2591 · DOI · Paper page
  5. 10.1038/nature11404 · DOI · Paper page
  6. 10.1038/nature11252 · DOI · Paper page
  7. 10.1038/cdd.2017.180 · DOI · Paper page
  8. 10.1093/jmcb/mjaa040 · DOI · Paper page
  9. 10.1038/ng0593-42 · DOI · Paper page
  10. 10.1093/bioinformatics/btv195 · DOI · Paper page
  11. 10.1038/nprot.2009.86 · DOI · Paper page
  12. DobinA DavisCA SchlesingerF et al.STAR: Ultrafast Universal RNA‐Seq Aligner.2013;29:15‐21. · DOI · Paper page
  13. LiBJBB DeweyCN.RSEM: Accurate Transcript Quantification from RNA‐Seq Data with or without a Reference Genome.2011;12:323. · DOI · Paper page
  14. 10.1016/S0092-8674(05)80006-6 · DOI · Paper page
  15. 10.1038/74624 · DOI
  16. 10.1038/312651a0 · DOI · Paper page
  17. 10.1111/j.1438-8677.2008.00168.x · doi:10.1111/j.1438-8677.2008.00168.x
  18. 10.1177/1947601911409747 · DOI · Paper page
  19. StommelJM MarchenkoND JimenezGS MollUM HopeTJ Wahl GMJTEj.A Leucine‐Rich Nuclear Export Signal in the p53 Tetramerization Domain: Regulation of Subcellular Localization and p53 Activity by NES Masking.1999;18:1660‐1672. · DOI · Paper page
  20. DerheimerFA ChangC‐W Ljungman MJEJoC.Transcription Inhibition: A Potential Strategy for Cancer Therapeutics.2005;41:2569‐2576. · DOI
  21. GravinaGL SenapedisW McCauleyD et al.Nucleo‐Cytoplasmic Transport as a Therapeutic Target of Cancer.2014;7:1‐9. · DOI · Paper page
  22. KauTR WayJC. Silver PAJNRCNuclear Transport and Cancer: From Mechanism to Intervention.2004;4:106‐117. · DOI · Paper page
  23. NieL HouJ ChuY‐Y et al.Compartmentalized Functions of Epidermal Growth Factor Receptor (EGFR) in Tumorigenesis and Malignant Phenotypes.2021;81:120. · doi:10.1158/1538-7445.am2021-120
  24. Le CamL LinaresLK PaulC et al.E4F1 Is an Atypical Ubiquitin Ligase that Modulates p53 Effector Functions Independently of Degradation.2006;127:775‐788. · DOI · Paper page
  25. 10.1158/1535-7163.MCT-06-0336 · DOI · Paper page
  26. 10.1002/ijc.20818 · DOI
  27. 10.1038/sj.onc.1202314 · DOI · Paper page
  28. 10.1038/cdd.2013.17 · DOI · Paper page
  29. 10.1016/j.ccell.2018.07.004 · DOI · Paper page
  30. 10.1093/carcin/22.1.89 · DOI
  31. 10.1002/gcc.2870090407 · DOI

Cited by

Metadata

Authors
Kim, J., Jung, J., Kim, K., Lee, J., & Im, Y.
Affiliations
  • Division of Hematology‐Oncology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea
  • Innovative Institute for Precision Medicine, Samsung Medical Center Seoul South Korea
  • Department of Pathology and Translational Genomics, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea
Venue
Cancer Medicine
Publisher
Wiley
Published
2023-04-20
Volume
12
Issue
11
Pages
12438-12451
ISSN
2045-7634
Cited by
38
References
6
Language
en
Funders
  • National Research Foundation of Korea (NRF‐2017R1D1A1B03028446, NRF‐2020R1F1A1072616)
  • Korea Health Industry Development Institute (HR20C0025)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.